Literature DB >> 12572835

Angiokeratoma corporis diffusum--Fabry disease: historical review from the original description to the introduction of enzyme replacement therapy.

H Fabry1.   

Abstract

This paper gives a brief historical overview of Fabry disease. First described in 1898 and called angiokeratoma corporis diffusum, a succession of observations and pioneering clinical research over the past 100 years has led to our present understanding of the disease. The major milestones during this time are described, as is the work that resulted in the successful introduction of enzyme replacement therapy.

Entities:  

Mesh:

Year:  2002        PMID: 12572835     DOI: 10.1111/j.1651-2227.2002.tb03102.x

Source DB:  PubMed          Journal:  Acta Paediatr Suppl        ISSN: 0803-5326


  10 in total

1.  Successful management of enzyme replacement therapy in related fabry disease patients with severe adverse events by switching from agalsidase Beta (fabrazyme(®)) to agalsidase alfa (replagal (®)).

Authors:  Kazuya Tsuboi; Hiroshi Yamamoto; Fuji Somura; Hiromi Goto
Journal:  JIMD Rep       Date:  2014-04-10

2.  Enzyme replacement therapy in a patient with Fabry disease and the development of IgE antibodies against agalsidase beta but not agalsidase alpha.

Authors:  Akemi Tanaka; Taisuke Takeda; Takao Hoshina; Kazuyoshi Fukai; Tsunekazu Yamano
Journal:  J Inherit Metab Dis       Date:  2010-06-22       Impact factor: 4.982

3.  A modified lipid composition in Fabry disease leads to an intracellular block of the detergent-resistant membrane-associated dipeptidyl peptidase IV.

Authors:  Katia Maalouf; Jia Jia; Sandra Rizk; Graham Brogden; Markus Keiser; Anibh Das; Hassan Y Naim
Journal:  J Inherit Metab Dis       Date:  2010-05-22       Impact factor: 4.982

4.  The Fabry disease-associated lipid Lyso-Gb3 enhances voltage-gated calcium currents in sensory neurons and causes pain.

Authors:  L Choi; J Vernon; O Kopach; M S Minett; K Mills; P T Clayton; T Meert; J N Wood
Journal:  Neurosci Lett       Date:  2015-02-16       Impact factor: 3.046

5.  Automatic lane segmentation in TLC images using the continuous wavelet transform.

Authors:  Bruno Moreira; António Sousa; Ana Maria Mendonça; Aurélio Campilho
Journal:  Comput Math Methods Med       Date:  2013-09-19       Impact factor: 2.238

6.  Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal).

Authors:  Kazuya Tsuboi; Hiroshi Yamamoto
Journal:  Genet Med       Date:  2012-04-12       Impact factor: 8.822

7.  Serum Biomarkers of Endothelial Dysfunction in Fabry Associated Cardiomyopathy.

Authors:  Jefferson Loso; Natalie Lund; Maxim Avanesov; Nicole Muschol; Susanne Lezius; Kathrin Cordts; Edzard Schwedhelm; Monica Patten
Journal:  Front Cardiovasc Med       Date:  2018-08-15

8.  A Case of a 50-Year-Old Woman with Typical Fabry Disease Who Showed Serial Electrocardiographic and Echocardiographic Changes over a 17-Year Period.

Authors:  Su Nam Lee; Gee-Hee Kim; Ki-Dong Yoo
Journal:  Case Rep Cardiol       Date:  2019-04-01

9.  Angiokeratoma Corporis Diffusum: An Uncommon Case with Suspected Anderson Fabry Disease.

Authors:  Priyanka Vadher; Pooja Agarwal; Amit Mistry; Krishna Gajjar; Nalini Bansal; Sabha Neazee
Journal:  Indian Dermatol Online J       Date:  2020-03-09

10.  Descriptive epidemiology of Fabry disease among beneficiaries of the Specified Disease Treatment Research Program in Japan.

Authors:  Kazuya Tsuboi; Sadao Suzuki; Masaki Nagai
Journal:  J Epidemiol       Date:  2012-06-09       Impact factor: 3.211

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.